---
figid: PMC10743660__ijms-24-17325-g006
figtitle: Inhibition of inflammation-induced EMT by PTs
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC10743660
filename: ijms-24-17325-g006.jpg
figlink: /pmc/articles/PMC10743660/figure/F6
number: F6
caption: Inhibition of inflammation-induced EMT by PTs. Lupane-, oleanane-, and ursane-type
  PTs exhibit a variety of EMT inhibition mechanisms. PTs inhibit TGF-β signaling
  pathways (UA, AA, celastrol, pristimerin, C DDO-Me) and the downstream SMAD (UA,
  AA, celastrol, β-peltoboykinolic acid, glycyrrhizin) and ERK (UA, UNA, OA) signaling
  axes. PT-induced disruption of integrin signaling involves integrin αVβ5 expression
  inhibition (UA) and activation of FAK and AKT (BA, SYK023). The blockade of F-actin
  polymerization by the lupane-type PTs BA and SYK023 is mediated by the downregulation
  of Synpo, which presumably activates Smurf1-dependent ubiquitination of RhoA. In
  contrast, BA disrupts the Skp2-SCF E3 ligase complex, thereby protecting E-cadherin
  from degradation. The ursane-type PTs UA and AA inhibit β-catenin through a GSK-β-dependent
  mechanism. The effect of UA on EMT is also associated with repression of the AEG-1
  oncogene, which regulates several steps in the NF-κB signaling pathway, and inhibition
  of the EGFR signaling pathway. Glycyrrhizin inhibits EMT induced by HMGB1, a nuclear
  protein released from tumor cells (TLR4 and RAGE are shown as possible HMGB1 receptors
  due to uncertainty in the downstream pathway). Some triterpenoids have an unknown
  mechanism of action but regulate EMT-associated genes (SM, evoditrilone A, pristimerin).
  Downward (↓) and upward (↑) arrows indicate downregulation and upregulation of expression,
  respectively
papertitle: 'The Nexus of Inflammation-Induced Epithelial-Mesenchymal Transition and
  Lung Cancer Progression: A Roadmap to Pentacyclic Triterpenoid-Based Therapies'
reftext: Kirill V. Odarenko, et al. Int J Mol Sci. 2023 Dec;24(24).
year: '2023'
doi: 10.3390/ijms242417325
journal_title: International Journal of Molecular Sciences
journal_nlm_ta: Int J Mol Sci
publisher_name: MDPI
keywords: inflammation | pulmonary malignancy | epithelial-to-mesenchymal transition
  | natural products | aggressiveness | tumor stem cells | mechanism of action
automl_pathway: 0.9612886
figid_alias: PMC10743660__F6
figtype: Figure
redirect_from: /figures/PMC10743660__F6
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10743660__ijms-24-17325-g006.html
  '@type': Dataset
  description: Inhibition of inflammation-induced EMT by PTs. Lupane-, oleanane-,
    and ursane-type PTs exhibit a variety of EMT inhibition mechanisms. PTs inhibit
    TGF-β signaling pathways (UA, AA, celastrol, pristimerin, C DDO-Me) and the downstream
    SMAD (UA, AA, celastrol, β-peltoboykinolic acid, glycyrrhizin) and ERK (UA, UNA,
    OA) signaling axes. PT-induced disruption of integrin signaling involves integrin
    αVβ5 expression inhibition (UA) and activation of FAK and AKT (BA, SYK023). The
    blockade of F-actin polymerization by the lupane-type PTs BA and SYK023 is mediated
    by the downregulation of Synpo, which presumably activates Smurf1-dependent ubiquitination
    of RhoA. In contrast, BA disrupts the Skp2-SCF E3 ligase complex, thereby protecting
    E-cadherin from degradation. The ursane-type PTs UA and AA inhibit β-catenin through
    a GSK-β-dependent mechanism. The effect of UA on EMT is also associated with repression
    of the AEG-1 oncogene, which regulates several steps in the NF-κB signaling pathway,
    and inhibition of the EGFR signaling pathway. Glycyrrhizin inhibits EMT induced
    by HMGB1, a nuclear protein released from tumor cells (TLR4 and RAGE are shown
    as possible HMGB1 receptors due to uncertainty in the downstream pathway). Some
    triterpenoids have an unknown mechanism of action but regulate EMT-associated
    genes (SM, evoditrilone A, pristimerin). Downward (↓) and upward (↑) arrows indicate
    downregulation and upregulation of expression, respectively
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TGFB1
  - TNF
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - LRP5
  - LRP6
  - HMGB1
  - MAFD1
  - LY86
  - TGFBR2
  - TGFBR1
  - TNFRSF1A
  - TLR4
  - EGFR
  - EGF
  - DVL1
  - DVL1P1
  - DVL2
  - DVL3
  - HSP90AA1
  - HSP90B1
  - TRAP1
  - HSP90AB1
  - MYD88
  - TRAF6
  - MTDH
  - UQCRFS1
  - RIPK1
  - RALBP1
  - KRR1
  - SHC1
  - AXIN1
  - AXIN2
  - APC
  - PROC
  - GSK3A
  - GSK3B
  - MAP3K7
  - NR2C2
  - CHUK
  - IKBKB
  - IKBKG
  - IKBKE
  - TBK1
  - CTNNB1
  - MAP2K2
  - MAP2K1
  - SMAD2
  - SMAD3
  - PDK1
  - PDPK1
  - RHO
  - RHOD
  - RHOA
  - RHOB
  - RHOC
  - SKP2
  - UXT
  - RBX1
  - SKP1
  - CUL1
  - RELA
  - SYT1
  - GORASP1
  - WNK1
  - CD40
  - ARHGEF7
  - ASCC1
  - H3P40
  - MAPK3
  - MAPK1
  - SMAD4
  - CDH1
  - FZR1
  - RPS6KA1
  - RPS6KA2
  - RPS6KA3
  - RPS6KA4
  - RPS6KA5
  - RPS6KA6
  - ACTA1
  - ACTA2
  - ACTB
  - ACTC1
  - ACTG1
  - ACTG2
  - HNF4A
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - SLC26A4
  - MPZL2
  - M6PR
  - SMURF1
  - AKT1
  - AKT2
  - AKT3
  - JAK2
  - SYNPO
  - MTOR
  - STAT3
  - RPS6KB1
  - RPS6KB2
  - EIF4EBP1
  - ITK
  - SLC22A3
  - SNAI1
  - MMP2
  - COL6A1
  - COL6A2
  - COL6A3
  - COL6A5
  - COL6A6
  - COL7A1
  - COL8A1
  - COL8A2
  - COL9A1
  - COL9A2
  - COL9A3
  - COL10A1
  - COL11A1
  - COL11A2
  - COL12A1
  - COL13A1
  - COL14A1
  - COL15A1
  - COL16A1
  - COL17A1
  - COL18A1
  - COL19A1
  - COL20A1
  - COL21A1
  - COL22A1
  - COL23A1
  - COL24A1
  - COL25A1
  - COL26A1
  - COL27A1
  - COL28A1
  - COL1A1
  - COL1A2
  - COL4A1
  - COL4A2
  - COL4A3
  - COL4A4
  - COL4A5
  - COL4A6
  - COL5A1
  - COL5A2
  - COL5A3
  - MMP9
  - SNAI2
  - CDH2
  - TIMP1
  - TJP1
  - TNF-a
  - Glc
  - EGF
  - Cel
---
